Matt cofounder Notable Labs in 2014. Currently his responsibilities include leading the overall vision and strategy, partnerships, recruiting, and any other company-related matters. Previously he was as a portfolio manager and trader at Clarium Capital, a global macro hedge fund. Matt started his career on a foreign exchange and interest rate sales and trading desk at Bank of America Merrill Lynch. Matt received his BA magna cum laude in Applied Economics and Management from Cornell University where he captained the cross country team and ran the 1,500 and 5,000 meter distance for the Big Red track team.
Designing Clinical Trials For Patients Not Drugs
Randomized controlled clinical trials have changed little since their inception. Bayesian statistical methods, technologies that stratify patients, and initial success in breast cancer should make adaptive trials more common. This talk will cover how adaptive trials benefit patients by making it more likely they receive an effective drug and benefit drug companies by reducing approval time and cost.
Oncologists are increasingly using technology to precisely diagnose the biological mechanisms driving a patient’s tumor, to predict which therapies are likely to be most effective in block-ing them, and to monitor the patient’s response in real time. Learn how these technologies are transforming the practice of oncology into a science.